EcoDrugPlus

Purinergic Receptor P2y2

Ensembl ID : ENSGACG00000008228
Gene Symbol: P2RY2
2 Cross references
199 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSGACG00000017178
Gene Symbol: P2RY4
2 Cross references
168 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSGACG00000008198
Gene Symbol: P2RY6
2 Cross references
183 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSGACG00000012991
Gene Symbol: RIPK1L
1 Cross references
198 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSGACG00000002191
Gene Symbol: RAMP1
1 Cross references
190 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSGACG00000014723
Gene Symbol: RAMP1
2 Cross references
183 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSGACG00000018193
Gene Symbol: RPTOR
1 Cross references
214 Possible Orthologues:

Renin

Ensembl ID : ENSGACG00000002847
Gene Symbol: REN
1 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSGACG00000003269
Gene Symbol: RET
1 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSGACG00000007999
Gene Symbol: RARB
2 Cross references
393 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSGACG00000009372
Gene Symbol: RARG
1 Cross references
383 Possible Orthologues:

Rho-Associated, Coiled-Coil Containing Protein Kinase 2a

Ensembl ID : ENSGACG00000012788
Gene Symbol: ROCK2A
1 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).